# Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

> **NCT07648264** · PHASE3 · RECRUITING · sponsor: **CSL Behring** · enrollment: 63 (estimated)

## Conditions studied

- Secondary Immune Deficiency

## Interventions

- **BIOLOGICAL:** IgPro20

## Key facts

- **NCT ID:** NCT07648264
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-15
- **Primary completion:** 2029-03-13
- **Final completion:** 2029-03-13
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2026-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07648264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07648264, "Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07648264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*